ATE422545T1 - Regulierung mittels atp binding cassette transporter proteins abc1 - Google Patents

Regulierung mittels atp binding cassette transporter proteins abc1

Info

Publication number
ATE422545T1
ATE422545T1 AT00942914T AT00942914T ATE422545T1 AT E422545 T1 ATE422545 T1 AT E422545T1 AT 00942914 T AT00942914 T AT 00942914T AT 00942914 T AT00942914 T AT 00942914T AT E422545 T1 ATE422545 T1 AT E422545T1
Authority
AT
Austria
Prior art keywords
abc1
regulation
atp binding
binding cassette
transporter proteins
Prior art date
Application number
AT00942914T
Other languages
English (en)
Inventor
Richard Lawn
David Wade
Michael Garvin
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE422545T1 publication Critical patent/ATE422545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
AT00942914T 1999-06-18 2000-06-16 Regulierung mittels atp binding cassette transporter proteins abc1 ATE422545T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14026499P 1999-06-18 1999-06-18
US15387299P 1999-09-14 1999-09-14
US16657399P 1999-11-19 1999-11-19

Publications (1)

Publication Number Publication Date
ATE422545T1 true ATE422545T1 (de) 2009-02-15

Family

ID=27385472

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00942914T ATE422545T1 (de) 1999-06-18 2000-06-16 Regulierung mittels atp binding cassette transporter proteins abc1

Country Status (19)

Country Link
EP (2) EP1218515B1 (de)
JP (4) JP2003506097A (de)
KR (2) KR100476519B1 (de)
CN (2) CN100513570C (de)
AR (2) AR024391A1 (de)
AT (1) ATE422545T1 (de)
AU (3) AU777461B2 (de)
BR (2) BR0011753A (de)
CA (2) CA2375787C (de)
DE (1) DE60041545D1 (de)
HK (2) HK1046427A1 (de)
IL (2) IL147022A0 (de)
MX (2) MXPA01013175A (de)
NO (2) NO20016121L (de)
NZ (3) NZ531401A (de)
SG (2) SG121853A1 (de)
TR (2) TR200200441T2 (de)
TW (2) TWI259205B (de)
WO (2) WO2000078971A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
EP1854880A1 (de) * 1999-03-15 2007-11-14 University of British Columbia Verfahren und Reagenzien zur Modulation von Cholesterinspiegeln
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
CA2382562A1 (en) * 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
MXPA02010684A (es) 2000-05-02 2003-03-10 Aventis Pharma Sa Secuencias de acido nucleico regulador del gen abc1.
EP1203588A1 (de) * 2000-11-06 2002-05-08 Bayer Ag Sterol-unabhängige Regulierung des ABC1 Promotors mit OncostatinM
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2003004692A2 (en) * 2001-07-03 2003-01-16 Xenon Genetics, Inc. Screening processes for agents modulating cholesterol levels
CA2463395A1 (en) * 2001-10-12 2003-04-24 Grelan Pharmaceutical Co., Ltd. Therapeutic agents for low hdl-cholesterolemia
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
EP1465869B1 (de) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulatoren von lxr
ES2367539T3 (es) 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
US8466143B2 (en) 2003-07-23 2013-06-18 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US8119686B2 (en) 2006-11-24 2012-02-21 Hykes Laboratories Llc Spiroquinone compound and pharmaceutical composition
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
EP2650311A3 (de) 2007-11-27 2014-06-04 Ablynx N.V. Gegen heterodimere Cytokine und/oder deren Rezeptoren gerichtete Aminosäuresequenzen und Polypeptide damit
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2414521B1 (de) * 2009-03-31 2016-10-26 The General Hospital Corporation Regulierung von mir-33-mikrornas bei der behandlung cholesterinspiegelbedingter erkrankungen
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
KR101676704B1 (ko) 2009-05-28 2016-11-16 엑셀리시스 페이턴트 컴퍼니 엘엘씨 Ｌｘｒ 조절자
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
AU2011328246B2 (en) 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
EP2723772A1 (de) 2011-06-23 2014-04-30 Ablynx N.V. Gegen ige gerichtete variable immunglobulin-einzeldomänen
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
US9101745B2 (en) * 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
CN105209039B (zh) 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
KR20180080337A (ko) 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
TW202417517A (zh) 2017-06-02 2024-05-01 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
CN118894939A (zh) 2017-06-02 2024-11-05 默克专利股份有限公司 结合adamts的免疫球蛋白
NZ759601A (en) 2017-06-02 2023-06-30 Merck Patent Gmbh Aggrecan binding immunoglobulins
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
IL296251A (en) * 2020-03-06 2022-11-01 Endolytix Tech Inc Compositions and methods for the treatment of intracellular bacterial infections
CN115433733B (zh) 2021-06-04 2025-12-12 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
CA3262070A1 (en) 2022-07-14 2025-06-13 Bio-Thera Solutions, Ltd. ANTI-NECTIN-4 ANTIBODIES AND THEIR USES
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
EP4731770A1 (de) 2023-06-22 2026-04-29 Ablynx NV Chimäre proteine zur modulation der cytokinrezeptoraktivität
CN118027196B (zh) 2023-06-25 2025-12-02 合肥天港免疫药物有限公司 抗cd3抗体及其应用
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
CN119569886A (zh) 2023-09-06 2025-03-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2025056575A1 (en) 2023-09-11 2025-03-20 Novo Nordisk A/S Anti il-6 domain antibodies
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
TW202543670A (zh) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑
TW202542180A (zh) 2023-12-22 2025-11-01 比利時商艾伯霖克斯公司 用於位點特異性胺軛合的基於蛋白質的載體
WO2025207946A1 (en) 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
US20260007757A1 (en) 2024-06-18 2026-01-08 Ablynx Nv Antibody-recruiting molecules
WO2026078159A1 (en) 2024-10-10 2026-04-16 Ablynx Nv Immune cell engagers and methods comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010684A (es) * 2000-05-02 2003-03-10 Aventis Pharma Sa Secuencias de acido nucleico regulador del gen abc1.

Also Published As

Publication number Publication date
WO2000078972A8 (en) 2001-06-21
EP1218515A2 (de) 2002-07-03
KR100476519B1 (ko) 2005-03-17
BR0011753A (pt) 2002-04-30
CA2375781A1 (en) 2000-12-28
CN100513570C (zh) 2009-07-15
NZ516061A (en) 2004-04-30
NZ529785A (en) 2005-09-30
JP2003506097A (ja) 2003-02-18
WO2000078971A2 (en) 2000-12-28
TWI304737B (en) 2009-01-01
IL147022A0 (en) 2002-08-14
JP4277956B2 (ja) 2009-06-10
NO20016114D0 (no) 2001-12-14
KR20020012612A (ko) 2002-02-16
SG121852A1 (en) 2006-05-26
SG121853A1 (en) 2006-05-26
WO2000078972A9 (en) 2002-07-18
KR20020012281A (ko) 2002-02-15
AU777461B2 (en) 2004-10-14
WO2000078972A2 (en) 2000-12-28
AU5743400A (en) 2001-01-09
AU2005200171A1 (en) 2005-02-10
NZ531401A (en) 2005-08-26
JP2003508031A (ja) 2003-03-04
NO20016121D0 (no) 2001-12-14
TW200626176A (en) 2006-08-01
WO2000078971A3 (en) 2002-01-17
TR200200441T2 (tr) 2002-11-21
TR200200440T2 (tr) 2002-09-23
MXPA01013174A (es) 2002-06-04
CA2375787C (en) 2007-03-27
BR0011696A (pt) 2002-04-30
HK1046708A1 (zh) 2003-01-24
NO20016121L (no) 2002-02-12
EP1218515B1 (de) 2009-02-11
NO20016114L (no) 2002-02-12
CN1434865A (zh) 2003-08-06
JP2005112859A (ja) 2005-04-28
CA2375787A1 (en) 2000-12-28
HK1046427A1 (zh) 2003-01-10
AR024576A1 (es) 2002-10-16
JP2006137750A (ja) 2006-06-01
EP1190065A2 (de) 2002-03-27
AR024391A1 (es) 2002-10-02
CN1379817A (zh) 2002-11-13
DE60041545D1 (de) 2009-03-26
MXPA01013175A (es) 2002-06-04
AU5746700A (en) 2001-01-09
TWI259205B (en) 2006-08-01
IL147021A0 (en) 2002-08-14
WO2000078972A3 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
ATE422545T1 (de) Regulierung mittels atp binding cassette transporter proteins abc1
NO20022751D0 (no) Basisforbindelse med forbedret proteininnhold
DE50015735D1 (de) Magnetisches lagersystem
IS5058A (is) Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki
IS6040A (is) Valdekoxib efnablöndur
DE60038268D1 (de) Kosmetische Zubereitungen
DE60045759D1 (de) Amid-verbindungen
DE60021839D1 (de) Gradientenlinse
FR2802447B1 (fr) Systeme vaporisateur rechargeable
DE60041300D1 (de) Sequentielle Bus-Architektur
DE10082436D2 (de) Wirbelsäulensegment
NO20021275L (no) Transgentproduserte fusjonsproteiner
DE60039385D1 (de) Magnetwiderstandselement
DE50004258D1 (de) Transportvorrichtung
FR2791348B1 (fr) POLYPEPTIDE Npt2B
DK1230369T3 (da) Polypeptidhormon phosphatonin
EP1223853A4 (de) Virtuelles telemikroskop
ATE278712T1 (de) Antikörper gegen plazentaprotein 13
NO20021244D0 (no) Subenhet-optimaliserte fusjonsproteiner
DE50009295D1 (de) Vernetzerfreie zubereitungen
NO20020794L (no) Meg-1-protein
DE50011910D1 (de) Kosmetische zubereitungen
DK199900145U3 (da) Selvkørende transportør
SK2893U (sk) Väzba
FI4248U1 (fi) Solmuke

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties